Relay Therapeutics (RLAY)
(Real Time Quote from BATS)
$6.25 USD
-0.28 (-4.29%)
Updated Nov 7, 2025 09:34 AM ET
2-Buy of 5 2
NA Value NA Growth NA Momentum NA VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RLAY 6.25 -0.28(-4.29%)
Will RLAY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RLAY based on the 1-3 month trading system that more than doubles the S&P 500.

Other News for RLAY
RLAY forms 1,2,3 Pullback Bullish on November 6
Bank of America Securities Sticks to Its Buy Rating for Relay Therapeutics (RLAY)
Decoding Relay Therapeutics Inc (RLAY): A Strategic SWOT Insight
Relay Therapeutics Reports Q3 2025 Financial Progress
Analysts Conflicted on These Healthcare Names: Intellia Therapeutics (NTLA), Relay Therapeutics (RLAY) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)